Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBI-200 DDI Study with Ritonavir or Cobicistat in Healthy Volunteers
NCT05692570Phase 1Completed
- Sponsor
- Pyramid Biosciences
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paltimatrectinib in NTRK fusion-positive solid tumors, sponsored by Pyramid Biosciences. Primary endpoints: Maximum Plasma Concentration at 11 days, Area Under the Concentration-Time Curve from time zero to last measurable concentration at 11 days and 3 more. Started Sep 2022; status: completed.
02
Drugs
paltimatrectinib
03
Conditions
NTRK fusion-positive solid tumors
Beyond the preview
Go deeper on NCT05692570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05692570.